GlassScriptPhysician profile
Lori NP Freeman
NPI 1912104043
$3,897.72
in general payments reported to CMS, 2019-2025
25 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2023: $572 · 2024: $1,746 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,574.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $648.96 | 2023-2025 | Airsupra, Breztri, Fasenra |
| Amgen INC. | $333.18 | 2024-2025 | Evenity |
| Abbott Laboratories | $272.30 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $228.93 | 2023-2025 | Shingrix, Arexvy |
| Corcept Therapeutics | $195.68 | 2025 | Korlym |
| Tris Pharma INC | $193.04 | 2024-2025 | Quillivant, Quillichew Er, Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $180.39 | 2024 | Uzedy, Austedo Xr |
| Medtronic, INC. | $138.83 | 2024 | Interstim |
| Mallinckrodt Hospital Products INC. | $129.51 | 2023 | Terlivaz |
| Sanofi Pasteur INC. | $128.10 | 2025 | |
| Abbvie INC. | $125.17 | 2024 | |
| Kyowa Kirin, INC. | $121.81 | 2024 | Crysvita |
| Edwards Lifesciences Corporation | $120.13 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Avanir Pharmaceuticals, INC. | $120.00 | 2021 | |
| Axsome Therapeutics, INC. | $112.17 | 2024 | Auvelity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $109.86 | 2025 | |
| Neurocrine Biosciences, INC. | $107.71 | 2023-2025 | Ingrezza |
| Genentech USA, INC. | $106.00 | 2021 | |
| Exeltis, USA INC. | $101.69 | 2024 | Slynd |
| Tactile Systems Technology INC | $101.45 | 2023 | Flexitouch Plus, Entre Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.93 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.38 | 2025 | |
| Sanofi-Aventis U.S. LLC | $60.78 | 2025 | |
| Idorsia Pharmaceuticals US INC | $46.24 | 2023 | Quviviq |
| Boston Scientific Corporation | $32.48 | 2025 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.